Stocks · News reference

SAB Biotherapeutics To Present SAB-142 Phase 1 Data In Type 1 Diabetes At EASD Meeting September 28-30

Sep 22, 2026, 12:33 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 13, 2026, 12:34 PMBenzinga Newsdesk
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
SABS
BenzingaAug 6, 2026, 11:36 AMBenzinga Newsdesk
SAB Biotherapeutics Q2 2026, Cash Balance Of $208.0M, Providing Runway Through 2028
SABS